I've gathered together some interesting Tweets about ovarian cancer research studies from the SGO 2023 Annual Meeting.
Botensilimab An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody and Balstilimab a PD-1 inhibitor
Botensilimab, BOT, a novel innate/adaptive
— Dee Sparacio (@womenofteal) March 27, 2023
immune activator, plus balstilimab
(anti-PD-1) in patients with recurrent
platinum refractory/resistant ovarian cancer, #SGOmtg #gyncsm Bockorny
BOT = CTLA 4 inhibitor, 1st in Human study ,heavily pretreated ORR 33%, pic.twitter.com/7sz5YtLTGa
Additional information https://www.cancernetwork.com/view/botensilimab-plus-balstilimab-yields-enduring-responses-in-r-r-ovarian-cancer
SOLAR Trial olaparib (Lynparza) with selumetinib (Koselugo) in patients with RAS-mutant gynecologic malignancies
Exciting data from the SOLAR trial presented by @ShannonWestin on the use of combination PARPi and MEKi for RAS mutated recurrent ovarian and endometrial cancer! #SGOmtg #oncsurgery @MDAndersonNews pic.twitter.com/sxPEFOcDMI
— Aaron Shafer (@aaronshafer99) March 27, 2023
Find additional information at https://www.onclive.com/view/dr-westin-on-outcomes-of-the-solar-trial-in-ras-mutant-gynecological-malignances
SOLO 1 trial results - 7 year overall survival reported
The 7-year results of SOLO1 study have reported!
— Yukio Suzuki (@yetii18) March 26, 2023
Amazingly they got a great durable benefits in OS as well as TFST/TSST, which means most of patients who recieved olaparib as maintenance therapy haven't experienced relapse.#SGOMtg pic.twitter.com/lYr6RHz8yl
Solo-1 7year follow up presented by Cara Matthews @SGO_org annual meeting. Survival benefits confirmed. No new safety signals. #SGOmtg #gyncsm pic.twitter.com/JP0qkEKkwc
— Annie Ellis (@Stigetta) March 26, 2023
Additional information may be found at https://www.onclive.com/view/dr-mathews-on-maintenance-olaparib-in-ovarian-cancer
NOVA trial Recurrent ovarian cancer - Niraparib (Zejula) did not produce a statistically significant overall survival (OS) benefit compared with placebo.
Dr. Ursula Matulonis presents Final OS and Safety for ENGOT-OV16/NOVA. No new safety signals. #SGOmtg #gyncsm pic.twitter.com/kG7gG39gWo
— Annie Ellis (@Stigetta) March 26, 2023
Minimally invasive surgery vs open surgery
Impressive results from @KJorgensenMD. Study of NCDB demonstrated improved overall survival w/ minimally invasive surgery as opposed to open interval tumor reductive surgery in advanced #OvarianCancer. The LANCE study will provide prospective data here #SGOMtg #oncsurgery #gyncsm pic.twitter.com/STE3UNz7zc
— Shannon Westin (@ShannonWestin) March 26, 2023
Neoadjuvant olaparib - improved surgical outcomes
After neoadjuvant talazoparib results in BRCAm BC (Litton J.K. 2017), neoadjuvant olaparib in #ovariancancer (with mutation in BRCA1/2, RAD51C/D, or PALB2) by @ShannonWestin shows outstanding surgical outcomes after only 2 cycles of olaparib, even in Stage IV pts #SGOMTG #SGO2023 pic.twitter.com/T4Rdk9pCJ5
— Allegra Rollo (@AllegraRollo) March 25, 2023
For additional information see https://www.onclive.com/view/neoadjuvant-olaparib-proves-feasible-aids-optimal-resection-in-brca-mutant-ovarian-cancer
mirvetuximab soravtansine-gynx (Elahere)
Learning more about Elahere a monoclonal antibody directed against folate receptor alpha in OC @ImmunoGenInc Industry Sponsored session ~ 35% patients w/ OC express high levels SORAYA trial #SGOMtg #gyncsm pic.twitter.com/y6ThbanbWs
— Dee Sparacio (@womenofteal) March 25, 2023
Steroid eye drops followed by lubricating eye drops and regular visits to an ophthalmologist should be scheduled . For more information see https://www.onclive.com/view/dr-matulonis-on-the-management-of-mirvetuximab-soravtansine-related-toxicities-in-fr-ovarian-cancer
venous thromboembolism (VTE)
Higher Incidence of Venous Thromboembolism Associated with Increasing Lines of Chemotherapy in Heavily Treated Ovarian Cancer Patients
— Dee Sparacio (@womenofteal) March 28, 2023
Lampert #SGOMtg #gyncsm single institution, VTE assoc w/ increasked # lines of treatment , > 50% of VTEs required hospitalization pic.twitter.com/DZFgpjzRgI
For additional information see https://www.medpagetoday.com/meetingcoverage/sgo/103793
If you would like to share additional ovarian cancer studies presented at SGO 2023 please mention in the comment section below. Thanks.
Stop by tomorrow to read Tweets that highlighted studies on equity, diversity at the meeting.
No comments:
Post a Comment